The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis

An in vivo model of coronary artery thrombosis in the conscious dog was used to evaluate the potential antithrombotic effect of nafazatrom (BAYg6575). A silver wire electrode was implanted in the left circumflex coronary artery (LCX) and was used at a later time to deliver a 50 μA anodal current for 24 hours to the intimal surface of the vessel. The resulting injury to the endothelium was accompanied by the adhesion, aggregation, and subsequent formation of an occlusive thrombus in the LCX of vehicle-treated dogs. Nafazatrom was given as an intravenous dose of 1 mg/kg for 48 hours, before anodal stimulation of the coronary artery was initiated, and was repeated every 6 hours during anodal stimulation for a total treatment period of 72 hours. As compared to vehicle-treated control dogs, the dogs treated with nafazatrom had smaller thrombi, preservation of coronary blood flow, a lesser degree of ischemic injury in the myocardial region subserved by the LCX, and less frequent premature ventricular complexes during the final 12 hours of the study period. Concomitant ex vivo platelet aggregation studies revealed significant inhibition of platelet aggregation in response to collagen and adenosine diphosphate in drug-treated dogs. The results of these investigations provide evidence that nafazatrom prevents in vivo development of occlusive coronary artery thrombi in response to disruption of the endothelial surface of the vessel. (Am Heart J 107:629, 1984.)

Ann Arbor, Mich.

From the Departments of Pharmacology and Internal Medicine (Cardiology), University of Michigan Medical School.

Supported by grant HL-27817 from the National Heart, Lung, and Blood Institute, by a grant-in-aid from Miles Laboratories, a fellowship from the Michigan Heart Association (Dr. Shea), and a Fellowship from the Pharmaceutica Manufacturer’s Association Foundation (Dr. Romson).

Received for publication Sept. 30, 1982; revision received Dec. 27, 1982; accepted Jan. 7, 1983.

Reprint requests: Benedict R. Lucchesi, Ph.D., M.D., Department of Pharmacology, The University of Michigan Medical School, M6322 Medical Science Building, Ann Arbor, MI 48109.

Preliminary work on nafazatrom suggested that this compound may act as a stimulator of prostacyclin release from the vessel wall. More recently, evidence suggests that nafazatrom may inhibit not only the prostacyclin degrading enzyme, but tissue and platelet lipoxygenases as well. In addition, this drug may also act as a free radical scavenger. In animals and humans, nafazatrom has had no effect on hemodynamics, blood coagulation, fibrinolysis, or
platelet aggregation in vitro.\textsuperscript{1,4} Nafazatrom has been effective in the prevention of experimental thrombosis caused by traumatically induced damage of vessel segments in the rat carotid artery and rabbit femoral artery.\textsuperscript{4} In the same models, nafazatrom has thrombolytic activity comparable to that of urokinase, although the mechanism is unclear.\textsuperscript{4} A recent report on streptozocin-induced diabetic rats indicated that the decreased aortic production of prostacyclin could be increased by administration of nafazatrom.\textsuperscript{5}

In view of the promising antithrombotic potential of nafazatrom, we investigated this drug in a conscious canine model of experimental coronary thrombosis.\textsuperscript{3} This model is appealing as it minimizes the effect of "physiologic reactance" as a result of general anesthesia and surgical stress.\textsuperscript{7} As a result, the cardiovascular, neural, and other physiologic responses more closely resemble the clinical state. In addition, pharmacologic doses of drugs easily tolerated by the anesthetized animal are often poorly tolerated by the conscious animal; thus the dosages of a drug given to the conscious animal will more closely resemble the clinical situation. In the present study, nafazatrom reduced the size of coronary thrombi as compared to control animals while maintaining coronary blood flow. As a consequence of these effects, the extent of myocardial ischemic injury and frequency of ventricular arrhythmias in the last 12 hours of study were reduced in the drug-treated animals. We also found significant inhibition of ex vivo platelet aggregation in nafazatrom-treated animals.

\textbf{METHODS}

\textbf{Surgical procedure.} Male mongrel dogs, 15 to 20 kg, were anesthetized with intravenous sodium pentobarbital (30 mg/kg) and artificially respirated. A lead II ECG was monitored throughout surgery. By means of aseptic technique, cannulae were placed in the left common carotid artery and jugular vein, then exteriorized through the nape of the neck. After left thoracotomy, the heart was suspended in a pericardial cradle and the proximal left circumflex coronary artery (LCX) was isolated from the surrounding tissues. A 28-gauge Teflon-coated silver wire with 5 mm of the tip of a 25-gauge hypodermic needle secured on the wire's leading end was inserted into the LCX and affixed to the heart with suture. An electromagnetic flow probe (Carolina Instrument Co.), precalibrated with whole blood, was placed on the LCX 2 to 3 mm proximal to the silver wire insertion and affixed to the heart (Fig. 1). Zero flow and calibration were established by transient total occlusion of the LCX followed by release. Coronary blood flow was measured with a square-wave electromagnetic flow meter (Carolina Medical Electronics, Inc.). The pericardium and chest were closed in layers. Grass disc electrodes were tunneled subcutaneously near the right foreleg and left hindleg, and were exteriorized along with the intracoronary wire and flow probe through the thoracotomy incision. The dogs were given a single intramuscular injection of ampicillin (3 mg/kg). Cannulae were flushed repeatedly with saline solution to maintain patency.

\textbf{Electrical stimulation of LCX and drug treatment.} On the morning after surgery, the animal's heart rate, blood pressure, ECG, and coronary blood flow were monitored. Animals were studied further only if: (1) they were free of ECG evidence of myocardial injury; (2) they had no evidence of significant arrhythmias (fewer than five premature ventricular contractions per minute; (3) they had a normal phasic pattern of coronary blood flow; and (4) they were fully recovered from surgery and ambulatory. Venous blood was drawn from a foreleg for platelet studies (\textit{vide infra}). Nafazatrom, 1 mg/kg, or saline solution was administered intravenously every 6 hours for a total of 12 doses (3 days). The nafazatrom was dissolved in 1 to 2 ml of 0.1N NaOH and diluted with saline solution to a final standard volume of 20 ml (pH 9). The control solutions of normal saline had 1 to 2 ml of NaOH included in the 20 ml injected volume. Animals were given drugs or control solutions according to a random number table.

After the fifth dose of drug or saline solution, venous blood was again drawn for platelet studies. After the eighth dose of drug or saline solution, anodal current from a 9-volt battery was delivered to the intimal surface of the LCX via the Teflon-coated wire. The current output of 50 uA was adjusted through a 250,000 ohm potentiometer placed in series. The subcutaneous electrodes were connected to a telemetry transmitter for transmission of the ECG signal. The potentiometer with battery and transmitter was held in a nylon jacket thus allowing the dog unrestricted movement. ECG data were received \textit{via} telemetry and in turn were recorded by an FM-tape.
Fig. 2. Representative example of the pulsatile and mean left circumflex coronary artery (LCX) blood flows in response to intraluminal electrical stimulation. Multiple reductions in flow are followed by reactive hyperemic responses with eventual total absence of flow.

recorder (Cardiocassette) programmed to cycle for 28 seconds every 15 minutes. The tape was played back later into a Grass polygraph for analysis of arrhythmias. The 90 μA current to the LCX was maintained for 24 hours and then discontinued. Venous blood was again drawn for platelet studies. The animals were monitored briefly for heart rate, blood pressure, ECG, and coronary blood flow. The animals were then anesthetized with sodium pentobarbital and the heart was exposed as described previously. Ventricular fibrillation was induced by DC current and the heart was removed. The LCX in the area of the wire insertion was dissected free and the artery was opened lengthwise. The wet thrombus was removed from the intima and weighed. The heart was then "bread-loafed" from apex to base into 0.7 cm thick transverse slices and incubated in 2,3,5-triphenyltetrazolium chloride (Sigma) for 30 minutes at 37°C. This dye stains normal tissues brick red by virtue of its reaction with myocardial dehydrogenases, while unstained irreversibly injured tissue appears pale. Both the nonstained and stained areas were removed and weighed so as to obtain a measurement of the extent of irreversible ischemic injury.

Platelet aggregation studies. Platelet aggregation studies were performed by means of previously described spectrophotometric methods, using a Bio/Data platelet aggregometer. Platelet-rich plasma was prepared by collecting venous blood in 1.0 ml of 3.8% sodium citrate to a total volume of 10 ml. This was centrifuged at 310 × g for 3 minutes to obtain the platelet-poor plasma fraction. Platelet-rich plasma was diluted with platelet-poor plasma to a platelet count of 200,000/mm² before use in the aggregation assays. All platelet samples were assayed within 1 hour of the time of phlebotomy. Aggregation was initiated under three different conditions with the use of a 50 μl aliquot of aggregating agent added to 450 μl of diluted platelet-rich plasma. Aggregating conditions included: collagen (1:80 dilution of Ethicon collagen dispersion—TD150), 5.0 μg adenosine diphosphate (Sigma), and arachidonic acid (Sigma) 0.65 mM with an additional 10 μl of L-epinephrine (Sigma), 0.55 μM in saline solution at pH 3.

Statistics. All data are expressed as the mean ± standard error of the mean. Student's t test for unpaired
Table II. Effect of nafazatrom (BAYg6575) on coronary thrombosis and infarction

<table>
<thead>
<tr>
<th></th>
<th>BAYg6575 (n = 9)</th>
<th>Saline solution (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombus wet weight (mg)</td>
<td>7.6 ± 1.0*</td>
<td>16.7 ± 3.7</td>
</tr>
<tr>
<td>Infarct (gm)</td>
<td>4.6 ± 1.5†</td>
<td>10.4 ± 1.2</td>
</tr>
<tr>
<td>Left ventricle (gm)</td>
<td>70.6 ± 2.9</td>
<td>77.8 ± 4.5</td>
</tr>
<tr>
<td>Infarct left ventricle (%)</td>
<td>6.1 ± 1.9†</td>
<td>14.0 ± 2.0</td>
</tr>
<tr>
<td>Total heart (gm)</td>
<td>110.9 ± 3.6</td>
<td>116.7 ± 6.0</td>
</tr>
</tbody>
</table>

*X ± SE.
†p < 0.05.

Table III. Effect of nafazatrom on ventricular arrhythmias after LCX stimulation

<table>
<thead>
<tr>
<th>Hours</th>
<th>PVC/heart rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BAYg6575 (n = 9)</td>
</tr>
<tr>
<td>0-6</td>
<td>1 ± 2*</td>
</tr>
<tr>
<td>7-12</td>
<td>12 ± 16</td>
</tr>
<tr>
<td>13-18</td>
<td>36 ± 12†</td>
</tr>
<tr>
<td>19-24</td>
<td>37 ± 12†</td>
</tr>
</tbody>
</table>

PVC = premature ventricular contractions.
*X ± SE.
†p < 0.05.

observed in the recorded ECG data. Fig. 4 is a transverse section from one of the hearts in the control group. Staining with triphenyltetrazolium chloride reveals an area of unstained tissue in the distribution of the LCX, which had undergone thrombotic occlusion. A summary of the data from the group of saline-treated control animals is contained in Tables I, II, and III.

Effects of nafazatrom in animals subjected to LCX injury. The acute administration of nafazatrom had no effect on heart rate, blood pressure, ECG morphology, or coronary blood flow. There was a trend for blood pressure to be decreased in some animals at the end of the observation period just before the time of death; however, the number of animals was too few for meaningful comparisons. Both electrical stimulation of the LCX and the mean coronary blood flows of the control and drug-treated groups were the same (21.1 ± 1.5 vs 21 ± 1.6 ml/min). At the end of LCX stimulation, the mean coronary blood flow was significantly greater in the drug-treated group than in the control group (Table I). For both groups, the reduction in mean coronary blood flow after LCX stimulation was significant as compared to the respective baseline states.
Thrombus wet weight was significantly smaller in the drug-treated group than the control group (Table II). Drug-treated animals tended to have smaller thrombi (<6 mg) associated with preservation of coronary blood flow in four animals. In three treated animals, large thrombi (>6 mg) were associated with absence of coronary blood flow. One animal with a small thrombus was associated with absent coronary blood flow, although no obvious focal spasm of the LCX was noted at the time of death. In control animals, all thrombi were associated with absent coronary flow except in one animal where a small thrombus was present with a markedly reduced coronary flow.

Left ventricular infarction was smaller in the drug-treated group than the control group (Table II). This difference was also apparent when infarction was expressed as a percentage of the left ventricular weight to correct for differences in heart weight. In two animals with occlusive thrombi there was minimal evidence of left ventricular infarction. Gross inspection of the heart in these two animals did not reveal extensive collateralization of vessels. Analysis of ventricular arrhythmias revealed significantly fewer arrhythmias in the drug-treated animals over the last 12 hours of electrical stimulation (Table III). In drug-treated animals, the fewest arrhythmias were noted in those animals with relative preservation of coronary blood flow. Representative tracings of the hemodynamic and ECG effects of drug and control treatment are noted in Figs. 5 and 6, respectively.

Ex vivo platelet aggregation studies revealed no significant differences between the drug and control groups for the baseline aggregating conditions. In the drug treated animals, platelet aggregation was significantly inhibited at both 24 and 72 hours when compared to the predrug baseline for two aggregating conditions: collagen and adenosine diphosphate (Fig. 7). No such differences were apparent for the arachidonic acid condition. A representative platelet aggregation curve is noted in Fig. 8. For the control group, a major difference was only apparent between 24 and 72 hours for two aggregating conditions: collagen and arachidonic acid (Fig. 9). No difference was apparent when the 24- and 72-hour values were compared to the predrug baselines for any of the aggregating conditions.
DISCUSSION

The hemodynamic effects of nafazatrom were negligible during acute administration as has been previously reported. This result is not surprising if one considers the proposed mode of action, that is, nafazatrom is not a prostacyclin agonist; rather it increases the availability of native prostacyclin. Our studies did not specifically evaluate the chronic hemodynamic effect of nafazatrom, although there was a trend for the blood pressure to be lower for some animals at the time of death. These results could be due to the effects of nafazatrom, hypovolemia, or myocardial infarction, and thus we cannot comment on their significance.

**Nafazatrom effect on coronary blood flow.** At the end of the experimental period (after electrical stimulation of the LCX), the coronary blood flow was greater in the treated animals than control animals. The preservation of coronary blood flow seemed to be related to the size of the arterial thrombus; larger thrombi were associated with smaller flows while small thrombi had a negligible

---

**Fig. 6.** Representative hemodynamics from an animal treated with nafazatrom (BAYg6575), 1 mg/kg every 6 hours intravenously. The “before” tracing represents the postsurgical recovery period before drug treatment or electrical stimulation. The “after” tracing represents the period after both drug treatment and 24 hours of electrical stimulation of the LCX.

**Fig. 7.** Effect of nafazatrom (BAYg6575) on ex vivo platelet aggregation. Each bar represents the mean ± SE for an aggregating condition at one of three time points: 0 hrs = predrug baseline; 24 hrs = after 24 hours of drug therapy; 72 hrs = after 72 hours of drug therapy, the last 24 hours of which includes the period of LCX electrical stimulation.
effect on coronary blood flow. It is not entirely clear what the primary drug effect is, that is, relief of coronary spasm or inhibition of thrombosis. It is possible that both events occur to some extent, and the drug may be affecting both processes.

Diltiazem, a calcium channel blocker with prominent vasodilatory properties, has been evaluated in this coronary thrombosis model and appears to have no antithrombotic effects. This would argue for the relative importance of the process of thrombosis in our model. However, one animal in the nafazatrom-treated group had a very small thrombus (~1 mg) associated with absent coronary blood flow, arguing for the potential importance of coronary spasm, at least in some animals. It seems likely that the beneficial effect of nafazatrom in preventing thrombosis while maintaining coronary blood flow has several facets: an increase in prostacyclin with its attendant antiaggregatory and vasodilatory properties; inhibition of lipooxygenase with attendant decreased production of vasoconstricting leukotrienes, and the poorly understood thrombolytic effect.

In the early stages of electrical stimulation there are several episodes of marked reduction of coronary blood flow followed by marked reactive hyperemia. Several such episodes will occur before the vessel becomes totally occluded. These episodes most likely represent transient thrombotic occlusion of the coronary vessel with subsequent distal microembolization of the fragmented thrombi. In both our drug-treated and control animals, these same events occur. The drug-treated animals have smaller thrombi at the site of intimal injury than control animals; however, the total amount of thrombus formed is unknown since some thrombus is embolized downstream. One can only speculate that the drug-treated animals' thrombi are less deleterious as judged by end points such as coronary blood flow or myocardial infarction (vid infra). It is important to recognize that the anodal current of 50 μA applied to the intimal surface of the circumflex vessel does not generate sufficient heat to produce protein denaturation and that the resulting thrombus mass is due to an interaction of the platelet with the denuded surface of the vessel.
Reduction in ultimate infarct size. Drug-treated animals had smaller left ventricular infarctions as compared to the control group. Maintenance of epicardial coronary blood flow is of major importance in this regard. However, two animals had occlusive thrombi yet there was minimal evidence of infarction. While extensive collateral networks were not evident in the two animals cited, functional collateral recruitment can occur, conceivably due to or independent of a drug effect. Within the ischemic zone as well as the border of the ischemic zone, prostacyclin may act not only as a vasodilator but also as an inhibitor of platelet microthrombus formation. An additional intriguing property of nafazatrom is its effect as a free radical scavenger, which may act to preserve ischemic myocardium.3 It would be of interest to study nafazatrom further in global ischemia or one of the occlusion-release models of experimental infarction to further delineate its effects on protecting against ischemic myocardial injury.12

Ventricular tachyarrhythmias. The frequency of ventricular arrhythmias in drug-treated animals was reduced over the last 12 hours of study. In our thrombosis model, total occlusion of the vessel usually occurs approximately 8 to 12 hours after initiation of electrical stimulation followed by ventricular arrhythmias 1 to 2 hours later. The beneficial effect in the drug-treated group reflects the expected time course as we do not expect to see major ventricular arrhythmias before 6 to 12 hours of stimulation. Understandably, the beneficial effect is most evident in those animals with preserved coronary blood flows and small left ventricular infarctions. Some animals with minimal evidence of decrease in coronary flow and left ventricular infarction will manifest ventricular arrhythmias. These animals will often have thrombosis of one of the distal LCX or marginal branches detected at necropsy. Our experimental protocol suggests that the decrease in ventricular arrhythmias in drug-treated animals is due to the lack of occlusive thrombosis of the LCX. We cannot exclude a primary antiarrhythmic effect of nafazatrom independent of its effects on the arachidonic acid pathway.

Previous studies of nafazatrom on platelet function have indicated no effect on in vitro or ex vivo platelet aggregation in the rat, rabbit, or human.1,4 Our studies of ex vivo platelet aggregation in dogs indicate significant inhibition of platelet aggregation in response to collagen and adenosine diphosphate. There was no significant response to arachidonic acid although an inhibitory trend was apparent. In the latter case, the marked variance in the baseline aggregating condition may explain the lack of statistical significance.

Modification of platelet reactivity. The inhibition of platelet aggregation in nafazatrom-treated animals is compatible with several potential mechanisms: an increase in arachidonic metabolites, which inhibit platelet aggregation (e.g., prostacyclin); a decrease in products of the lipoxygenase pathway, which stimulate platelet aggregation (leukotrienes); or inhibition of platelet proaggregatory products (e.g., thromboxane). The previously documented lack of an in vitro effect of nafazatrom in view of our ex vivo platelet aggregation result argues for the nafazatrom-stimulated production of a substance by the organism for the inhibition of platelet aggregation, most likely prostacyclin. The relative role of leukotriene blockade in the inhibition of platelet aggregation is unclear, although in vitro studies in human platelets suggest an important role.13 It is unclear why we noted inhibition of platelet aggregation while others have not. Differences may lie in methodology or in the species tested: the dog in our model, and rat, rabbit, and humans in other reports. Our studies also differ in that the drug was given for 72 hours before ex vivo testing of platelet function.

For control animals there was no difference in the aggregation responses at 24 and 72 hours as compared to the baseline predrug response; however, there was an increase in the 24-hour aggregation response relative to the baselines for collagen and

![Graph](attachment:image.png)
Coronary antithrombotic effects of nafazatrom

There were also significant differences between the 24- and 72-hour aggregation responses. It is unlikely that the responses are due to hyperaggregable platelets in the postoperative period (e.g., due to tissue injury) as one would expect the predrug baselines to be higher. These results are of uncertain significance.

Conclusions. We have demonstrated beneficial antithrombotic effects of nafazatrom in an experimental model of coronary thrombosis. With inhibition of coronary thrombosis, we noted a relative preservation of coronary blood flow and a decrease in the degree of infarction and frequency of ventricular arrhythmias as compared to control animals. Concomitant ex vivo platelet aggregation studies suggest that the antithrombotic effect is, in part, related to inhibition of platelet aggregation.

REFERENCES

11. Polis J: Personal communication.